Session 5: ETS Gene Fusions
Session Chairperson: Mark A. Rubin, Cornell University Weill Medical College, New York, NY
8:30 a.m.-10:00 a.m.
[8:30-9:00]
Recurrent SPOP mutations define a distinct molecular subclass of prostate cancer
Mark A. Rubin
[9:00-9:30]
Novel therapeutic targets in prostate cancer
Arul M. Chinnaiyan, University of Michigan, Ann Arbor, MI
[9:30-9:45]
Context-specific oncogenesis by ETS-family transcription factors
Yu Chen, Memorial Sloan-Kettering Cancer Center, New York, NY
[9:45-10:00]
PARP1 inhibition as a strategy for targeting ETS gene fusions
Felix Feng, University of Michigan, Ann Arbor, MI
|
Session 6: Prostate Cancer Initiation and Progression
Session Chairperson: Michael Shen, Columbia University Medical Center, New York, NY
10:20 a.m.-11:50 a.m.
[10:20-10:50]
Stem cells and the origin of prostate cancer
Michael Shen
[10:50-11:20]
Mechanisms and therapeutic targets in metastatic prostate cancer
Karen Cichowski, Brigham and Women's Hospital, Cambridge, MA
[11:20-11:50]
Stem cells and prostate cancer
Owen N. Witte, University of California, Los Angeles, CA
|
Session 7: Late-Breaking Research
Session Co-Chairpersons: Charles L. Sawyers, Memorial Sloan-Kettering Cancer Center, New York, NY, and Arul M. Chinnaiyan, University of Michigan, Ann Arbor, MI
2:30 p.m.-5:00 p.m.
[2:30-2:45]
Altered AR gene architecture and splicing in castration-resistant prostate cancer
Scott M. Dehm, University of Minnesota, Masonic Cancer Center, Minneapolis, MN
[2:45-3:00]
Cooperation between androgen receptor and polycomb in prostate cancer
Jindan Yu, Northwestern University Lurie Comprehensive Cancer Center, Chicago, IL
[3:00-3:15]
A bad influence: ERG, AR, and prostate cell differentiation
Raymond A. Pagliarini, Novartis Institutes for BioMedical Research, Cambridge, MA
[3:15-3:30]
Transcriptional programs directed by the androgen receptor splicing variants
Jun Luo, Johns Hopkins University, Baltimore, MD
[3:30-3:45]
* Oncogenic ETS over-expression mimics RAS/MAPK signaling in prostate cells
Peter C. Hollenhorst, Indiana University, Bloomington, IN
[3:45-4:00]
* Optimization and applications of a tissue slice culture model of the normal and malignant human prostate
Sophia L. Maund, Stanford University, Stanford, CA
[4:00-4:15]
* The snoRNP assembly factor SHQ1 is a novel prostate cancer tumor suppressor gene
Phillip J. Iaquinta, Memorial Sloan-Kettering Cancer Center, New York, NY
[4:15-4:30]
* Biochemical recurrence is not a definitive surrogate endpoint for development of clinically useful predictive models for post-prostatectomy patients
Anamaria Crisan, GenomeDx, Vancouver, BC, Canada
[4:30-4:45]
* Therapeutic targeting of oncogene-specific tyrosine kinase networks during prostate cancer progression
Justin M. Drake, University of California, Los Angeles, CA
[4:45-5:00]
* Cabozantinib (XL184) inhibits androgen-sensitive and castration-resistant prostate cancer in the bone and increases bone formation in non-tumored bones
Eva Corey, University of Washington, Seattle, WA
|